Hot Investor Mandate 4: Corporate VC Invests in Devices and Diagnostics Up to 18 Months Prior to Clinical Trials

16 Feb

The venture arm of a medtech corporation makes equity investments in life science companies, typically in venture rounds. The firm invests at a wide range of product development phases, from preclinical development (up to 18 months away from the first in-human clinical trials) to products that have received regulatory approval, but typically does not invest in products that are on the market. The fund is open to considering investments globally.

The firm invests in areas that are strategically important to its parent corporation, primarily the medical device sector and the diagnostics sector. Within diagnostics, the fund is interested in molecular diagnostics, point of care diagnostics, and immunoassay and clinical chemistry systems. The firm’s areas of interest include cardiovascular diseases, diabetes and ophthalmology. The fund also invests in infant nutrition and nutraceuticals.

The firm invests only in privately-held companies, but has no other fixed requirements for companies & management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: